SCHEMBL7560540

SCHEMBL7560540

O=C(N/N=C\c1cccnc1)c1[nH]c2ccccc2c1-c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.61
MAPT P10636 5/20 0.61
MEN1 O00255 4/20 0.59
KMT2A Q03164 4/20 0.59
SMN1; SMN2 Q16637 2/20 0.58
POLB P06746 1/20 0.58
PADI4 Q9UM07 1/20 0.55
ALDH1A1 P00352 3/20 0.55
PAX8 Q06710 2/20 0.55
KDM4E B2RXH2 2/20 0.55
RAB9A P51151 4/20 0.54
HPGD P15428 2/20 0.52
GAA P10253 1/20 0.52
ASF1A Q9Y294 1/20 0.52
TUBB4A P04350 2/20 0.52
TUBB P07437 2/20 0.52
TUBA3C P0DPH7 2/20 0.52
TUBA1B P68363 2/20 0.52
TUBA4A P68366 2/20 0.52
TUBB4B P68371 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7560543 1.00 LMNA (0.61) LMNAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL7560504 0.95 MAPT (0.55) LMNAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL7560498 0.95 MAPT (0.55) LMNAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL7559093 0.89 KMT2A (0.53) LMNAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL7559100 0.89 KMT2A (0.53) LMNAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL7559063 0.89 MEN1 (0.51) LMNAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL7559066 0.89 MEN1 (0.51) LMNAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL7567198 0.89 MAPT (0.75) LMNAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL7567200 0.89 MAPT (0.75) LMNAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL7560031 0.88 MAPT (0.65) LMNAMAPTMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US claimed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 WO claimed
US-6323228-B1 INHIBITING ANGIOGENESIS IN A MAMMAL IN RECOGNIZED NEED OF SUCH TREATMENT COMPRISING ADMINISTERING TO THE MAMMAL WITH INDOLE SUBSTITUTED WITH HYDRAZIDES ABBOTT LABORATORIES 2001-11-27 US claimed
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US disclosed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 WO disclosed
US-6323228-B1 INHIBITING ANGIOGENESIS IN A MAMMAL IN RECOGNIZED NEED OF SUCH TREATMENT COMPRISING ADMINISTERING TO THE MAMMAL WITH INDOLE SUBSTITUTED WITH HYDRAZIDES ABBOTT LABORATORIES 2001-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors MKI67, FLT4, IDO1 LMNA 4535/4885MAPT 4828/4885MEN1 3165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.